Acute Problems during Low-Dose-Rate Intracavitary Brachytherapy for Cervical Carcinoma

Wollschlaeger, Karin; Connell, Philip P.; Waggoner, Steven; Rotmensch, Jacob; Mundt, Arno J.

doi:10.1006/gyno.1999.5627

Cited by 10 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study there was no correlation between the type of anaesthesia and the rate of 'acute complications' during low-dose-rate intracavity brachytherapy in 128 patients. 2 Our data do not support the superiority of any particular anaesthesia technique.…”

Section: Discussioncontrasting

confidence: 70%

“…These data are in accordance with a report of 170 low-dose-rate intracavity brachytherapy procedures performed on 128 cervical carcinoma patients. 2 In gynaecologic brachytherapy 95% of patients are treated more than four times. 3 Our data indicate that ASA III or IV patients often receive repeated brachytherapy treatments such that about 40% of all anaesthetic procedures are carried out on ASA III or IV patients (Table 4).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anaesthesia for brachytherapy—5½ yr of experience in 1622 procedures

Benrath

Kozek-Langenecker

Hüpfl

et al. 2006

British Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Anaesthesia for brachytherapy—5½ yr of experience in 1622 procedures

Benrath

Kozek-Langenecker

Hüpfl

et al. 2006

British Journal of Anaesthesia

View full text Add to dashboard Cite

show abstract

“…The overall incidence of fever/infection, nausea/vomiting, and dizziness in this study was 7.2% (IC/ISBT routine group: 7.9%, IC/ISBT continuous group: 5.2%), 11.5% (IC/ISBT routine group: 11.1%, IC/ISBT continuous group: 12.5%), and 2.6% (IC/ISBT routine group: 2.8%, IC/ISBT continuous group: 2.1%), respectively. In previous studies, the incidence of fever/infection during the BT was 2.47–14.7% [ 13 – 15 ]. Only very few studies reported the incidence of anesthesia-related toxicities, which varied substantially in different anesthesia methods and postoperative analgesic methods; specifically, the incidence of dizziness was 0–33.3% [ 16 , 17 ], and the incidence of nausea and vomiting after the recovery from the general anesthesia was 0–21% [ 16 , 18 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study

et al. 2023

View full text Add to dashboard Cite

Purpose This study retrospectively compared the clinical and toxicity outcomes for the cervical cancer of the MRI-guided two adaptive brachytherapy (IGABT) fractions versus one IGABT fraction in one application. Methods One hundred and twenty patients with cervical cancer received external beam radiotherapy combined with or without concurrent chemotherapy, which was followed by the IGABT. The IGABT in 63 patients had one IGABT in each application (Arm 1), while in the other 57 patients, at least one treatment was two continuous IGABT every other day in one application (Arm 2). Clinical outcomes including overall survival (OS), cancer specific survival (CSS), progression free survival (PFS), local control (LC) were analyzed. Brachytherapy-related toxicities were evaluated, which included pain, dizziness, nausea/vomiting, fever/infection, blood loss during the removal of applicator and needles, the deep venous thrombosis, and other acute toxicities. The Common Terminology Criteria for Adverse Events (CTC-AE 5.0) was used to evaluate the incidence and severity of toxicities of the urinary system, lower digestive system, and reproduction system. Kaplan–Meier and the Log-rank test were used to analyze the clinical outcomes. Results The median follow-up time of the patients in Arm 1 and Arm 2 was 23.5 and 12.0 months, respectively. The overall treatment time was significantly shorter in Arm 2 than Arm 1 (60 vs. 64 d; P = 0.017). The OS, CSS, PFS, and LC in Arm1 and Arm 2 was 77.8% vs. 86.0% (P = 0.632), 77.8% vs. 87.7% (P = 0.821), 68.3% vs. 70.2% (P = 0.207), and 92.1% vs. 94.7% (P = 0.583), respectively. The highest NRS of the pain during brachytherapy waiting period (2.22 ± 1.84 vs. 3.02 ± 1.65; P < 0.001) and at the time of the removal of the applicator (4.69 ± 1.49 vs. 5.30 ± 1.18; P < 0.001) in the patients who received one hybrid intracavitary and interstitial brachytherapy (IC/ISBT) in one application and two continuous IC/ISBT every other day in one application were significantly different. So far four patients with grade 3 late toxicities have been reported. Conclusions The findings of this study demonstrated that the two continuous IGABT every other day in one application is a logistically applicable, safe, and effective treatment strategy that could shorten the overall treatment time and reduce the medical cost, comparing with the one IGABT in one application.

show abstract

“…The first of these difficulties is the fact that patients who are planned for brachytherapy are already elderly, and that these patients have a high risk of perioperative complications. [1,2] Second, intracavitary brachytherapy and interstitial brachytherapy are extremely painful and require both analgesia and immobilization. The American Brachytherapy Association also recommends the use of conscious sedation for intracavitary high-dose rate (HDR) applications of patients with cervical cancer whenever possible.…”

Section: Introductionmentioning

confidence: 99%

Anesthesia Techniques in Brachytherapy

Yıldırım¹

2019

TJ Oncol

View full text Add to dashboard Cite

Acute Problems during Low-Dose-Rate Intracavitary Brachytherapy for Cervical Carcinoma

Cited by 10 publications

References 19 publications

Anaesthesia for brachytherapy—5½ yr of experience in 1622 procedures

Anaesthesia for brachytherapy—5½ yr of experience in 1622 procedures

The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study

Anesthesia Techniques in Brachytherapy

Contact Info

Product

Resources

About